Difference between revisions of "LINC00973"
| (3 intermediate revisions by the same user not shown) | |||
| Line 10: | Line 10: | ||
LncBook ID: [https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289076 HSALNT0289076] | LncBook ID: [https://bigd.big.ac.cn/lncbook/transcript?transid=HSALNT0289076 HSALNT0289076] | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
===Characteristics === | ===Characteristics === | ||
| − | + | Please input characteristics information here. | |
===Expression=== | ===Expression=== | ||
| + | Please input expression information here. | ||
===Regulation=== | ===Regulation=== | ||
| + | Please input regulation information here. | ||
===Function=== | ===Function=== | ||
| − | + | LINC00973 were recently identified as powerful biomarkers of poor prognosis of colorectal cancer patients, predicting early tumor relapses.<ref name="ref2" /> | |
| + | |||
| + | LINC00973 may form a complex with lncRNA CRNDE. This RNA is a part of the Polycomb repressive complex 2, which epigenetically silences DUSP/CDKN1A expression, promoting proliferation and suppressing apoptosis of colon cancer cells.<ref name="ref2" /> | ||
===Disease=== | ===Disease=== | ||
| − | + | colorectal cancer <ref name="ref1" /><ref name="ref2" /> | |
===Evolution=== | ===Evolution=== | ||
| Line 42: | Line 32: | ||
==Labs working on this lncRNA== | ==Labs working on this lncRNA== | ||
| − | + | * Yangtai Yuhuangding Hospital, Zhifu District, Yantai, Shandong Province, China.<ref name="ref1" /> | |
| + | * Engelhardt Institute of Molecular Biology, The Russian Academy of Sciences, 119991, Moscow, Russia.<ref name="ref2" /> | ||
==References== | ==References== | ||
| Line 48: | Line 39: | ||
<ref name="ref1"> Diao R, Mu X, Wang T, et al. Risk score based on ten lncRNA-mRNA expression predicts the survival of stage II-III colorectal carcinoma[J]. PLoS One, 2017, 12: e0182908. | <ref name="ref1"> Diao R, Mu X, Wang T, et al. Risk score based on ten lncRNA-mRNA expression predicts the survival of stage II-III colorectal carcinoma[J]. PLoS One, 2017, 12: e0182908. | ||
</ref>(1) | </ref>(1) | ||
| + | |||
| + | <ref name="ref2">Zinovieva OL, Grineva EN, Prokofjeva MM, et al. Expression of long non-coding RNA LINC00973 is consistently increased upon treatment of colon cancer cells with different chemotherapeutic drugs[J]. Biochimie, 2018, 151: 67-72.</ref>(2) | ||
</references> | </references> | ||
Latest revision as of 06:05, 12 August 2019
Contents
Annotation
Name
Approved symbol: LINC00973
Approved name: long intergenic non-protein coding RNA 973
HGNC ID: HGNC:48868
Alias symbols: CTD-2021J15.2
LncBook ID: HSALNT0289076
Characteristics
Please input characteristics information here.
Expression
Please input expression information here.
Regulation
Please input regulation information here.
Function
LINC00973 were recently identified as powerful biomarkers of poor prognosis of colorectal cancer patients, predicting early tumor relapses.[1]
LINC00973 may form a complex with lncRNA CRNDE. This RNA is a part of the Polycomb repressive complex 2, which epigenetically silences DUSP/CDKN1A expression, promoting proliferation and suppressing apoptosis of colon cancer cells.[1]
Disease
Evolution
Please input evolution information here.
Labs working on this lncRNA
- Yangtai Yuhuangding Hospital, Zhifu District, Yantai, Shandong Province, China.[2]
- Engelhardt Institute of Molecular Biology, The Russian Academy of Sciences, 119991, Moscow, Russia.[1]
References
- ↑ 1.0 1.1 1.2 1.3 Zinovieva OL, Grineva EN, Prokofjeva MM, et al. Expression of long non-coding RNA LINC00973 is consistently increased upon treatment of colon cancer cells with different chemotherapeutic drugs[J]. Biochimie, 2018, 151: 67-72.
- ↑ 2.0 2.1 Diao R, Mu X, Wang T, et al. Risk score based on ten lncRNA-mRNA expression predicts the survival of stage II-III colorectal carcinoma[J]. PLoS One, 2017, 12: e0182908.
